Medy-Tox Inc. (KOSDAQ:086900)

Market Cap	1.03T
Revenue (ttm)	237.99B
Net Income (ttm)	21.25B
Shares Out	7.02M
EPS (ttm)	2,677.00
PE Ratio	54.76
Forward PE	24.50
Dividend	1,100.00 (0.75%)
Ex-Dividend Date	Sep 27, 2024

Volume	35,004
Average Volume	38,209
Open	148,900
Previous Close	146,600
Day's Range	143,300 - 148,900
52-Week Range	112,100 - 218,000
Beta	0.39
RSI	38.41
Earnings Date	Aug 12, 2025

About Endeavor Group Holdings

Medy-Tox Inc. operates as a biopharmaceutical company in South Korea. It provides botulinum toxin products, including Neuronox, a lyophilized white power for injection that is used to treat foot deformities due to spasticity in pediatric cerebral palsy patients; INNOTOX, a colorless transparent liquid-filled injection that is used to temporarily improve moderate to severe glabellar wrinkles; and Coretox, a lyophilized white power for injection that is used to temporarily improve moderate to severe glabellar wrinkles. The company also offers hya...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 724
• Stock Exchange: KOSDAQ
• Ticker Symbol: 086900

Financial Performance

In 2024, Medy-Tox's revenue was 228.62 billion, an increase of 3.39% compared to the previous year's 221.12 billion. Earnings were 15.98 billion, an increase of 82.00%.